MX2022005679A - Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. - Google Patents
Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden.Info
- Publication number
- MX2022005679A MX2022005679A MX2022005679A MX2022005679A MX2022005679A MX 2022005679 A MX2022005679 A MX 2022005679A MX 2022005679 A MX2022005679 A MX 2022005679A MX 2022005679 A MX2022005679 A MX 2022005679A MX 2022005679 A MX2022005679 A MX 2022005679A
- Authority
- MX
- Mexico
- Prior art keywords
- indene
- dihydro
- pharmaceutically acceptable
- acceptable salt
- same
- Prior art date
Links
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title abstract 6
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical group C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 abstract 3
- 108091000114 ceramide glucosyltransferase Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 abstract 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 208000015872 Gaucher disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000022292 Tay-Sachs disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona un nuevo compuesto que tiene una fracción de 2,3-dihidro-1H-indeno o de 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable del mismo, un proceso para la preparación del mismo, una composición farmacéutica que comprende el mismo y un uso del mismo. El compuesto que tiene una fracción de 2,3-dihidro-1H-indeno o de 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable del mismo tiene una actividad inhibitoria contra la glucosilceramida sintasa (GCS) y, por lo tanto, puede aplicarse de forma útil para prevenir o tratar diversas enfermedades asociadas a la GCS, como la enfermedad de Gaucher, la enfermedad de Fabry, la enfermedad de Tay-Sachs, la enfermedad de Parkinson, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146679 | 2019-11-15 | ||
| PCT/KR2020/015864 WO2021096238A1 (en) | 2019-11-15 | 2020-11-12 | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005679A true MX2022005679A (es) | 2022-06-27 |
Family
ID=75911374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005679A MX2022005679A (es) | 2019-11-15 | 2020-11-12 | Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230002379A1 (es) |
| EP (2) | EP4389744B1 (es) |
| JP (2) | JP7671751B2 (es) |
| KR (1) | KR20210059632A (es) |
| CN (2) | CN118955495A (es) |
| AU (1) | AU2020384066B2 (es) |
| BR (1) | BR112022009409A2 (es) |
| CA (1) | CA3154313A1 (es) |
| ES (1) | ES2984255T3 (es) |
| MX (1) | MX2022005679A (es) |
| PL (1) | PL4041733T3 (es) |
| RS (1) | RS65662B1 (es) |
| WO (1) | WO2021096238A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019058393A1 (en) | 2017-09-22 | 2019-03-28 | Jubilant Biosys Limited | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD |
| FI3697785T3 (fi) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidatsopyridiiniyhdisteitä pad:n estäjinä |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| CA3216293A1 (en) * | 2021-05-11 | 2022-11-17 | Dong-Hoon Kim | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the sam |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| CA3268132A1 (en) * | 2022-10-24 | 2024-05-02 | Yuhan Corporation | NEW DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE SALT AND ITS PREPARATION PROCESSES |
| AU2023368362A1 (en) * | 2022-10-24 | 2025-03-20 | Green Cross Corporation | Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| KR20250117295A (ko) * | 2024-01-26 | 2025-08-04 | 주식회사유한양행 | 고셔병의 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| EP2594565B1 (en) | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| UA118248C2 (uk) * | 2011-03-18 | 2018-12-26 | Джензім Корпорейшн | Інгібітори глюкозилцерамідсинтази |
| WO2013059119A1 (en) * | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| US10227323B2 (en) * | 2013-09-20 | 2019-03-12 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2019079626A1 (en) * | 2017-10-19 | 2019-04-25 | Samumed, Llc | 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
-
2020
- 2020-11-12 US US17/755,843 patent/US20230002379A1/en active Pending
- 2020-11-12 CN CN202410840972.5A patent/CN118955495A/zh active Pending
- 2020-11-12 BR BR112022009409A patent/BR112022009409A2/pt unknown
- 2020-11-12 EP EP24163536.6A patent/EP4389744B1/en active Active
- 2020-11-12 PL PL20887669.8T patent/PL4041733T3/pl unknown
- 2020-11-12 JP JP2022527911A patent/JP7671751B2/ja active Active
- 2020-11-12 RS RS20240700A patent/RS65662B1/sr unknown
- 2020-11-12 CA CA3154313A patent/CA3154313A1/en active Pending
- 2020-11-12 ES ES20887669T patent/ES2984255T3/es active Active
- 2020-11-12 WO PCT/KR2020/015864 patent/WO2021096238A1/en not_active Ceased
- 2020-11-12 MX MX2022005679A patent/MX2022005679A/es unknown
- 2020-11-12 AU AU2020384066A patent/AU2020384066B2/en active Active
- 2020-11-12 CN CN202080075084.9A patent/CN114829361B/zh active Active
- 2020-11-12 EP EP20887669.8A patent/EP4041733B1/en active Active
- 2020-11-12 KR KR1020200150785A patent/KR20210059632A/ko active Pending
-
2025
- 2025-04-21 JP JP2025069586A patent/JP2025111591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118955495A (zh) | 2024-11-15 |
| ES2984255T3 (es) | 2024-10-29 |
| AU2020384066A1 (en) | 2022-04-21 |
| RS65662B1 (sr) | 2024-07-31 |
| BR112022009409A2 (pt) | 2022-08-09 |
| JP2023503830A (ja) | 2023-02-01 |
| EP4041733C0 (en) | 2024-05-08 |
| EP4389744A1 (en) | 2024-06-26 |
| PL4041733T3 (pl) | 2024-09-23 |
| US20230002379A1 (en) | 2023-01-05 |
| EP4041733A4 (en) | 2023-08-30 |
| CN114829361A (zh) | 2022-07-29 |
| JP2025111591A (ja) | 2025-07-30 |
| AU2020384066B2 (en) | 2025-10-30 |
| CN114829361B (zh) | 2024-07-16 |
| EP4041733B1 (en) | 2024-05-08 |
| WO2021096238A1 (en) | 2021-05-20 |
| EP4389744B1 (en) | 2025-12-03 |
| CA3154313A1 (en) | 2021-05-20 |
| EP4041733A1 (en) | 2022-08-17 |
| JP7671751B2 (ja) | 2025-05-02 |
| KR20210059632A (ko) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005679A (es) | Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| BR112022002581A2 (pt) | Inibidores heterocíclicos de rip1 quinase | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| EP4344743A3 (en) | Heterocyclic flavone derivatives, compositions, and methods related thereto | |
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| PH12021551998A1 (en) | Novel heterotricyclic derivative compound and use of same | |
| ZA202100352B (en) | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | |
| WO2011159124A3 (ko) | Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 | |
| PH12021551268A1 (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| ATE430743T1 (de) | Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken | |
| NZ745210A (en) | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor | |
| WO2016126085A3 (ko) | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| MX2023007446A (es) | Compuesto heterociclico aromatico, composicion farmaceutica y uso de estos. | |
| MX2021002878A (es) | Inhibidores de cd73 y usos farmaceuticos de los mismos. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12021550572A1 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| MX2023012541A (es) | Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan. | |
| WO2018060962A3 (en) | Metformin amino acid compounds and methods of using the same |